Protein targets of nitazenes and their metabolites in human cells
Official title: Protein target identification of nitazenes and their metabolites using structural and chemoproteomics
Funded at Battelle Pacific Northwest Laboratories · NIH-11440279 · Data updated 2026-11-12
Researchers will map which human brain, heart, and lung proteins interact with nitazene opioids, helping explain why these drugs can be so potent and dangerous.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Battelle Pacific Northwest Laboratories NIH-funded |
| Lab location | 1 site (Richland, United States) |
| Project start | August 15, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $505,790 |
| NIH project number | 1R21DA066888-01 |
| Project ID | NIH-11440279 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research does not enroll patients; it analyzes human cell models to identify protein targets relevant to nitazene effects.
✕Less likely to help
There is no direct patient participation in this project.
What this research studies
This project aims to identify the specific human proteins that nitazene drugs bind to in brain, heart, and lung cells using special chemical probes. It will combine affinity-based profiling to find direct nitazene-binding proteins with a structural proteomics method to see how binding changes protein shape and function. The study will generate molecular-level data that links nitazene interaction to altered cellular signaling, which could illuminate why these opioids cause severe adverse effects. Findings could guide safer therapeutic strategies and inform overdose prevention efforts.
Why it matters
Potential benefit: If successful, the work could reveal molecular targets and pathways affected by nitazenes, helping develop better treatments for nitazene-related overdoses and informing public health responses.
How similar studies have gone: Proteomics and structural proteomics approaches have successfully identified drug-protein interactions in other compounds, supporting this methodology’s potential.
Where this research is happening
-
Battelle Pacific Northwest Laboratories
Richland, United States Active
Researchers
- Principal investigator: Lin, Vivian S — Battelle Pacific Northwest Laboratories
- Study coordinator: Lin, Vivian S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.